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Children undergoing cardiac operations in which eardiopulmonary bypass 
is used are at risk of significant postoperative blood loss. The acquired 
coagu!opathy is complex but is thought to be due, in part, to excessive 
fibrinolysis. We examined the possibility of reducing postoperative blood 
loss in children by using the antifibrinolytic drug tranexamic acid. Using a 
prospective, randomized, double-blind study design, we administered a 
single dose of tranexamic acid (50 mg/kg intravenously) or saline placebo, 
before skin incision, in 88 children undergoing cardiac operations. Post- 
operative blood loss and fluid replacement were recorded for the next 24 
hours. In addition, hemoglobin, platelet counts, and coagulation measures 
were recorded every 6 hours. When all patients were examined, there was no 
significant difference in postoperative blood loss between the treated and 
placebo groups (21.2 -+ 12 ml/kg per 24 hours, tranexamic acid, vs 27.2 -- 
20.3 mls/kg per 24 hours, placebo). However, when the children with 
cyanosis were analyzed separately, there was a highly significant difference 
in blood loss between the groups during the first 6 hours (11.2 -+ 3.7 ml/kg 
per 6 hours, tranexamic acid, vs 27.2 -- 11.4 mls/kg per 6 hours, placebo; 
p < 0.002), as well as the overall 24 hour study period (23.7 -- 7.5 mls/kg 
per 24 hours, tranexamic acid, vs 48.9 -+ 27.6 mls/kg per 24 hours, placebo; 
p < 0.02). Also significantly less blood and blood products were adminis- 
tered to the treated cyanosed group. Tranexamic acid produced a signifi- 
cant reduction in postoperative blood loss and blood product requirements 
in children with cyanosis undergoing heart operations. The drug had no 
effect in children without cyanosis or those requiring a second thoracotomy. 
(J Thorac Cardiovasc Surg 1996;111:982-7) 
C hildren undergoing cardiac bypass operations are at risk of significant postoperative bleeding. 1' 2 Ac- 
cording to one of our own studies, 3 the average child 
loses 30 ml/kg, roughly half the child's blood volume, 
in the first 24 hours after a routine cardiac operation. 
Many lose significantly more than this. It is commonly 
claimed that children with cyanosis and those under- 
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going a second thoracotomy are at particular isk of 
excessive blood loss? Apart from the cost associated 
with large transfusions, the patient is also exposed to 
the dangers of blood transfusion s and, in some cases, 
reoperation. 2 The most common finding at the second 
thoracotomy is a generalized ooze of blood from the 
surgical field, suggesting an acquired coagulopathy 
induced by cardiac bypass. 
Many abnormalit ies of coagulation have been 
described after cardiac surgery, 1' 6 including throm- 
bocytopenia, thrombocytopathy, decreased clotting 
factors, increased fibrinolysis, inadequate heparin 
neutralization, and disseminated intravascular coag- 
ulation. Despite the difficulty of determining which 
abnormality is most significant, the consensus is that 
the main cause of nonoperat ive blood loss after 
cardiopulmonary bypass is a combination of exces- 
sive fibrinolysis 7 and an acquired platelet defect. 1 
Consequently, attempts have been made to reduce 
blood loss with the use of antifibrinolytic drugs. 8' 9 
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Fibrinolysis follows reversible binding between 
lysine residues in fibrin and specific receptor sites in 
plasminogen. Reversible inhibition of absorption by 
lysine analogs, such as epsilon aminocaproic acid or 
tranexamic acid, displaces plasminogen and effec- 
tively inhibits fibrinolysis. 1° Earlier studies used 
epsilon aminocaproic acid, but a newer drug, tran- 
examic acid, is roughly ten times more potent, has a 
longer half-life, and is now more commonly used. 
Both drugs have few side effectsJ 1 The naturally 
occurring inhibitor of proteolysis, aprotinin, is used 
less often than lysine analogs because of its high 
cost. Plasmin also binds to platelets and activates 
them. Inhibiting this step with lysine analogs has 
been shown to preserve platelet adenosine diphos- 
phate levels, 12 as well as to decrease blood loss] 3 
Both epsi!on aminocaproic acid 14' is and tranex- 
amic acid 13' 16 have been shown to reduce blood loss 
in adults, although not in all studies. 17 Only one 
pediatric study has shown a slight benefit that was 
more pronounced in cyanotic children is We inves- 
tigated the possible benefit of antifibrinolytic ther- 
apy in children by use of a double-blind, random- 
ized, prospective study of tranexamic acid versus 
saline placebo in 88 patients undergoing cardiac 
bypass operations. 
The primary objective of this study was to inves- 
tigate whether a single preoperative dose of tranex- 
amic acid affects the amount of blood loss after 
cardiopulmonary b pass in children undergoing car- 
diac operations. The secondary study objective was 
to investigate that effect in two high-risk subgroups: 
children with cyanotic heart disease, and those with 
a history of previous thoracotomy. 
Methods 
The study was conducted in the Intensive Care Unit at 
the British Columbia's Children's Hospital. All operations 
were performed by the same two cardiac surgeons. Post- 
operative management was provided by three pediatric 
intensivists. Ethical approval was obtained from the Clin- 
ical Screening Committee of the University of British 
Columbia. Eighty-eight consecutive patients requiring 
cardiac operations were enrolled. All legal guardians were 
aware of the study and gave informed consent. Preenroll- 
ment exclusion criteria consisted of a history of hematuria, 
renal failure, previous thrombotic episodes, or past bleed- 
ing complications. 
Study design. Using a system of sealed envelopes, we 
allocated the patients to one of two groups: the treatment 
group received a single 50 mg/kg intravenous dose of 
tranexamic acid (Cyclokapron, Kabi Pharmacia, Missis- 
sauga, Ontario, Canada) and a control group received an 
equivalent volume of saline placebo. Drugs were admin- 
istered by the anesthetist before the first skin incision. 
Only the pharmacist was aware of the patient reatment 
groups. 
Because no literature exists concerning the use of 
tranexamic acid in pediatric heart surgery, the dose range 
had to be extrapolated from adult work. Unfortunately, 
literature recommendations range from 7 mg/kg 12 to 100 
to 120 mg/kg. 19 It is generally claimed that 10 to 15 mg/kg 
of tranexamic acid inhibits fibrinolysis in normal sub- 
jects.S, lO In discussion with the surgical service in Toronto 
General Hospital, who have extensive xperience with the 
drug, 19 we decided on a single preoperative dose of 50 
mg/kg given by slow intravenous infusion. Because the 
drug was given before the first skin incision, we did not 
alter the dose to account for subsequent differences in 
bypass priming volume. 
Because stimates of intraoperative blood loss are too 
inaccurate for study purposes, we collected and measured 
total chest tube drainage in 6, 12, and 24 hour blocks, 
starting from the time of chest closure. No correction was 
made for the hematocrit value of chest tube blood. In 
addition, the total amount of blood products transfused, 
hemostatic parameters (prothrombin time, partial throm- 
boplastin time, platelets, and fibrinogen), hemoglobin, 
and urine output were also recorded every 6 hours. 
Five percent albumin was used to replace all chest ube 
losses. The indication to administer blood or other blood 
products was at the discretion of the attending intensivists 
who where blinded to the group assignment of the pa- 
tients. 
Sample size calculation. Using blood loss over the first 
postoperative 24 hours as our primary outcome, we ex- 
pected the mean blood loss to be 25 ml/kg per 24 hours 
with a standard eviation of 75%. We wanted to be able to 
detect a difference of at least 50% in the treatment group. 
Choosing an a of 0.05, and a/3 of 0.2 (power of 80%), 
the sample size calculation yields 36 patients in each 
group. To compensate for patient exclusions, we arbi- 
trarily increased this number by 20% to give 44 children in 
each group. 
Statistical analysis. All values are expressed as mean _+ 
standard eviation. Discrete differences between the two 
groups were compared by unpaired t test except for 
within-group comparisons of preoperative and postoper- 
ative coagulation data, when a paired t test was used. 
Frequency data were compared by means of Fisher's exact 
test. Serial measurements, such as blood loss with time, 
were compared by means of repeated measures analysis of 
variance, followed by Duncan's multiple range post hoc 
test for significant values of F. In keeping with many pilot 
studies, it was necessary to make multiple statistical 
comparisons. To compensate for the increased chance of 
a type I error, the commonly accepted level of significance 
was halved to 2.5%. 
Results 
Patient exclusions. No patients met the preen- 
rollment exclusion criteria. Of the 88 patients en- 
rolled, six were excluded during the study period. 
Three of these, all from the placebo group, were 
returned to the operating room for mediastinal 
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Table I. Patient characteristics 
Variable Tranexamic acid Placebo 
No. of patients 40 42 
Age (too) 62.8 _+ 58.1 52.6 ± 51.2 
Age range 1 day-14 years 6 days-13 years 
Weight (kg) 21.3 ± 16.9 16.4 ± 12.5 
Bypass time (min) 80.5 _+ 42.1 73.6 ± 31.6 
Cmssclam p time (min) 48.9 _+ 29.3 (n = 37) 47.6 ± 26.5 (n = 42) 
Circulatory arrest ime (min) 20.7 _+ 16.6 (n = 13) 15.7 _+ 10.6 (n = 17) 
Male/female 19/21 21/2 !
Down syndrome 2 5 
Previous thoracotomy 14 10 
CYan0tic heart disease 8 10 
Type of repair 
ASD repair (primum and secundum) 16 10 
VSD repair 9 7 
Tetralogy of Fallot repair 1 5 
Bidirectional Glenn shunt 0 3 
Fontan operation 4 2 
Arterial switch operation 1 1 
Pulmonary artery conduit 3 2 
Aortic valvotomy 2 5 
Mitral valve replacement 0 2 
Others 4 5 
ASD, Atrial septal defect; VSD, ventricular septal defect. 
Table IL Preoperative and immediate postoperative coagulation results for the two treatment groups 
Tranexamic acid (n = 40) Placebo (n = 42) 
Preoperative Postoperative Preoperative Postoperative 
Hemoglobin (gm/L) 130.5 _+ 21.4 112.8 ± 20.8 132.0 _+ 21.9 114.5 + 21.7 
Hematocrit 0.376 ± 0.058 0.326 _+ 0.056 0.380 ± 0.061 0.329 -+ 0.060 
Prothrombin time (sec) 12.5 ± 1.0 14.9 ± 1.3 12.3 ± 0.6 14.9 -+ 1.1 
Partial thromboplastin ime (sec) 31.3 _+ 2.9 36.2 _+ 10.3 3!.4 -+ 4.1 37.8 ± 8.5 
Platelet count (×109/L) 312.8 ± 99.7 160.5 ± 59.1 328.2 ± 91.5 159.1 ± 68.5 
All within-grou p preoperative and postoperative differences are significant (p < 0.05). None of the between-group comparisons achieved significance. 
exploration during the first 24 hours because of 
excessive bleeding. A surgical cause for the blood 
loss was found in each case. In two other cases, also 
from the placebo group, the study code was broken 
at the request of the treating intensivist because of 
excessive blood loss. Both patients were given intra- 
venous tranexamic acid and large infusions of blood 
products. Neither patient required reoperation. A 
sixth patient, from the tranexamic acid group, had 
hypotension on arrival in the intensive care unit. 
After the patient had been given large volumes of 
blood products, the surgical site was reexplored. No 
active bleeding was found. The child had an overt 
disseminated coagu!opathy but subsequently made a 
good recovery. The reexploration rate in our study 
was 4.6%, similar to the proportion reported in the 
literature, z No patients died and no side effects were 
attributed to the treatment group. 
Patient characteristics. The characteristics n the 
remaining 82 patients are shown in Table I. Apart 
from minor differences in the type of procedure, the 
groups are comparable with respect o age, weight, 
gender, and duration of bypass, crossclamp, and 
circulatory arrest times. Frequencies of cyanotic 
lesions, Down syndrome, and repeated thoracoto- 
mies were also comparable. 
Postoperative blood loss. Preoperative and im- 
mediate postoperative (measured immediately after 
chest closure) coagulation results for the two groups 
are displayed in Table II. The postbypass coagulopa- 
thy in this study was typical of our earlier experi- 
ence. 3Significant within-group reductions were ob- 
served in hemoglobin value and platelet count, 
accompanied by significant increases in prothrom- 
bin time and activated partial thromboplastin time. 
However, no significant differences were seen when 
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Table III. Postoperative blood loss 
Variable Tranexarnic Acid Placebo p Vahte 
No. of patients 40 42 
0-6 hr 9.3 -+ 6.7 13.7 ± 10.8 0.03 
6-12 hr 4.2 _+ 2.8 5.0 + 4.6 NS 
12-24 hr 7.7 -+ 5.1 8.4 ± 7.6 NS 
Overall 24 hr 21.2 ± 12.0 27.2 _+ 20.3 NS 
All blood loss volumes are measured in milliliters per kilogram. NS, Not 
significant. 
Table IV. Postoperative blood loss' in the cyanotic 
subgroup 
Variable Tranexamic acid Placebo p Value 
No. of patients 8 10 
0-6 hr 11.2 _+ 3.7 27.2 + 11.4 0.002 
6-12 hr 5.5 _+ 2.6 7.6 ± 6.3 NS 
12-24 hr 7.1 +_ 3.6 14.1 ± 11.2 NS 
Overall 24 hr 23.7 -+ 7.5 48.9 ± 27.6 0.02 
All blood loss volumes are measured in milliliters per kilogram. NS, Not 
significant. 
the treatment and placebo groups were compared, 
including postoperative fibrinogen levels (1.43 _+ 
0.31 gm/L placebo, versus 1.60 ± 0.32 gin/L, tran- 
examic acid; p = not significant). Postoperative 
blood losses in the two treatment groups are shown 
in Table III. No significant difference in total blood 
loss was seen between the treated and placebo 
groups when all children were analyzed together. 
Second thoracotomy and cyanotic subgroups. 
The number of patients within the study was suffi- 
cient to examine the effect of tranexamic acid in two 
high-risk subgroups: children with cyanotic heart 
disease and those with a history of a previous 
thoracotomy. Table IV shows that blood loss in the 
subgroup with cyanosis was almost halved after 
treatment with tranexamic acid (23.7 ± 7.5 vs 46.9 _+ 
27.6 ml/kg per 24 hours; p < 0.02). Table V shows 
that tranexamic acid appears to have no effect at all 
in the acyanotic subgroup, either in total blood loss 
or in any of the measured time blocks (20.6 ± 12.8 
mls/kg per 24 hours, tranexamic acid, vs 20.4 ± 12.7 
mls/kg per 24 hours, placebo). Apart from a signif- 
icant difference in hemoglobin levels between chil- 
dren with and without cyanosis (153.3 _+ 26.9 gin/L, 
cyanosis, vs 125.1 _+ 14.6 gin/L, without cyanosis; 
p = 0.01), there were no other differences in preop- 
erative blood work, including prothrombin time, 
partial thromboplastin time, platelet count, or fi- 
brinogen level. In addition to reducing blood loss in 
the children with cyanosis, significantly fewer pa- 
tients with cyanosis required packed red cell trans- 
Table V. Postoperative blood loss in the acyanotic 
subgroup 
Variable Tranexamic acid Placebo p Value 
No. of patients 32 32 
0-6 hr 8.9 -- 7.2 9.5 -- 6.2 NS 
6-12 hr 3.9 ± 2.8 4.3 + 3.6 NS 
12-24 hr 7.8 _+ 5.3 6.6 ± 4.9 NS 
Overall 24 hr 20.6 ± 12.8 20.4 + 12,7 NS 
All blood loss volumes are measured in milliliters per kilogram. NS, Not 
significant. 
Table VI. Twenty-four-hour postoperative blood 
loss in second thoracotomy and first thoracotomy 
subgroups 
Tranexamic 
acid Placebo 
Blood Blood p 
No. loss No. loss Value 
Previous thoracotomy 14 20.9 _+ 9.2 10 28.7 ÷ 24.3 NS 
First thoracotomy 26 21.4 ± 13.3 32 26.8 _+ 18.9 NS 
Previous thoracotomy 4 28.4 ± 3.8 5 44.2 ± 25.9 NS 
and cyanosis 
All blood losses are measured inmilliliters per kilogram per 24 hours. NS, 
Not significant. 
fusions (1/8, tranexamic acid, vs 7/10, placebo; p = 
0.02) and platelet ransfusions (0/8, tranexamic acid, 
vs 6/10, placebo; p = 0.01). 
The situation was similar in the second thoracot- 
omy subgroup. A nonsignificant trend for greater 
blood loss in the placebo-treated, second thoracot- 
omy group is shown in Table VI. The same table 
shows that this difference is largely explained by the 
reduced blood loss in children with second thoracot- 
omies who had cyanosis. Patient numbers were too 
small to achieve significance. 
Discussion 
Preoperative administration f tranexamic acid to 
a representative group of children undergoing car- 
diac operations did not produce a significant reduc- 
tion in blood loss except during the first 6-hour time 
block. This difference was entirely due to the drug's 
effect on children with cyanosis, in whom tranexamic 
acid roughly halved postoperative blood loss and 
significantly reduced blood product requirements. 
The drug had no effect in acyanotic children or those 
requiring a second thoracotomy. In common with 
DeLeon and associates, 4 we found cyanosis, but not 
second thoracotomy, tobe a risk factor for excessive 
blood loss. 
When blood loss is a measured end point, the 
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exclusion of patients because of excessive blood 
losses runs the risk of experimental bias. We also 
analyzed the results with those who bled heavily 
included and found that this did not alter the study's 
final conclusions. Of the six patients excluded for 
heavy bleeding, five were from the placebo group 
and four had cyanosis. Inclusion of these patients in 
the analysis simply strengthened the difference in 
blood loss between the subgroups with cyanosis. 
Because there was still no significant drug effect in 
the patients without cyanosis, the study's conclu- 
sions were unchanged. 
Several articles have reported reduced postoper- 
ative blood loss after the use of preoperative tran- 
examic acid in adult patients, ' 9 Direct comparison 
with adult work is difficult because the study popu- 
lations differ widely: the mean age is much higher, 
the majority of patients have coronary artery dis- 
ease, and very few have cyanotic lesions or Down 
syndrome. In addition, there is no uniformity in drug 
dosage or administration. Some studies use contin- 
uous infusions of antifibrinolytic drugs, ~6 and others 
give a single drug dose, usually before bypass 2° but 
occasionally after bypass. 17 Even the size of the 
single dose varies by an order of magnitude from 7 
mg/kg t2 up to more than 100 mg/kg. 19 
There is no other report on the use of tranexamic 
acid in pediatric heart surgery, but some comparison 
can be made with McClure and Izsak, is who re- 
ported a significant reduction in blood loss in chil- 
dren receiving the antifibrinolytic drug epsilon ami- 
nocaproic acid. The effect was more pronounced in
those children with cyanotic lesions and was con- 
fined to the intraoperative p riod. 
It is not immediately obvious why tranexamic acid 
exerts its effect on blood loss. There is a large and 
sometimes contradictory literature concerning 
blood loss after cardiopulmonary b pass. Earlier 
work 2° tended to stress the importance of excessive 
fibrinolysis, but as the technology of cardiopulmo- 
nary bypass has improved, more recent work in this 
area emphasizes the importance of an acquired 
platelet defect. 2 We performed only simple clot- 
based estimates of coagulation (see Table II) and 
were unable to show any significant differences 
between the children with and without cyanosis, 
except for the widely described rise in hemoglobin 
concentration after chronic hypoxia. 21 Suarez and 
associates, 22 using biochemical markers of hemosta- 
sis in children with cyanotic ongenital heart dis- 
ease, showed highly significant increases in throm- 
boxane, platelet factor IV, and/3-thromboglobulin, 
indicating marked activation of the platelet system. 
They were unable to demonstrate any evidence of 
increased fibrinolytic activity. Tranexamic acid may 
improve hemostasis after surgery in two ways: It 
blocks plasmin-induced platelet activation, conse- 
quently preserving platelet function12; in addition, it
is an effective inhibitor of fibinolysis. Whether one 
or either of these mechanisms is responsible for its 
effect in children is not possible to tell with our 
present study design. 
More work is required to define the exact role of 
tranexamic acid in the control of bleeding after 
cardiac operations in children. In particular, a dose- 
response study is necessary because it is possible 
that repeat postoperative doses or a continuous 
infusion of tranexamic acid may improve the drug's 
effect. In addition, detailed studies of coagulation 
will be necessary to define the exact mode of action 
of this drug in the postbypass coagulopathy of 
children. 
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